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We investigated the effect of aminoguanidine (AG)
administration on GBM thickness, glomerular hep-
aran sulfate (HS) content, and urinary albumin and
HS excretion in diabetic rats. After induction of
diabetes, female Wistar rats were divided into 2
groups: Group AGDM (n 11) received lg/L amino-
guanidine bicarbonate in drinking water, group DC
(n 12) was given only tap water. Control rats re-
ceived AG (group AGH, n 8) or tap water (group
HC, n=8). At the end of a period of 8 weeks,
urinary albumin and glycosaminoglycan (GAG)
excretion was detected. GBM heparan sulfate dis-
tribution and count was determined under the elec-
tron microscope. The AGDM group had lower
urinary albumin and GAG excretion than diabetic
controls. GBM thickness was increased in diabetic
rats compared to groups of AGDM and HC. In
AGDM group alcian blue stained particle distribu-
tion and count in the GBM was similar to healthy
controls. In conclusion AG prevents the decrease
of anionic charged molecules in the GBM and
GBM thickening. This can be one of the mechan-
isms by which AG decreases albuminuria in dia-
betic rats.
Keywords: Aminoguanidine; Albuminuria; Glomerular
basement membrane; Anionic charge; Heparan sulfate;
Diabetes
Abbreviations: AGDM, aminoguanidine treated diabetic rats;
DC, diabetic controls; HC, healthy controls; AGH, amino-
guanidine treated healthy rats
INTRODUCTION
Thickening of the glomerular basement mem-
brane (GBM) and albuminuria are the charac-
teristic features of diabetic nephropathy. I1-31
Biochemical alterations of GBM subsequent to
increased non-enzymatic glycation of structural
proteins and formation of advanced glycosyla-
tion end products (AGE) have been invoked in
the genesis of an altered size and charge-selec-
tive barrier.I4-61 Aminoguanidine, a hydrazine
compound that inhibits glycosylation, prevents
diabetic complications. It has been shown to
decrease the widening of GBM, I7’81 limiting
mesangial expansionI8,91 and to reducing albu-
minuriaI9-121 in experimental diabetes. Although
we do not yet understand the exact mechanism
of action of this compound, our hypothesis is
that the benefical effects of AG on diabetic kid-
ney could be by preventing the loss of glomeru-
lar anionic charge. The aim of this study is to
evaluate the effects of AG on glomerular base-
ment membrane charge selectivity.
For the determination of glomerular an-
ionic change, we have measured the following
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parameters: albuminuria, which reflects the de-
fect in glomerular permeability, I131 red blood cell
anionic charge (RBCCh) that mirrors the electro-
static charge on the glomerular basement mem-
brane,I141 urine glycosaminoglycan, which is the
major elements of glomerular anionic barrier, as
an marker of GAG loss from GBM,[5-17] and the
glomerular basement membrane heparan sulfate
particles distribution and count that represent
the charge selective barrier.Il
MATERIAL AND METHODS
Forty, 10-week old female Wistar rats were used
in the study. Following an overnight fast, rats
were made diabetic by the injection of 55mg/kg
streptozotocin (Sigma USA, Mo) in sodium cit-
rate buffer (PH 4.5) via the intraperitoneal route.
After 1 week of the diabetes induction 11 rats
were given Aminoguanidine bicarbonate salt
(Sigma cat no: A-7259) ad lib in drinking water
at a concentration of I gr/L (group AGDM). Re-
maining rats were given only tap water and
were followed as diabetic controls (group DC,
n=12). Sixteen rats received an equivalent
amount of buffer intraperitoneal and half of
them served as healthy control rats (group HC),
while the other half were given AG I gr/L in
drinking water (group AGH).I,81
Water bottles were refilled everyday in all
groups of rats. Antidiabetic therapy was not
given to any group throughout the study period.
Rats were kept in light (12 hours light, 12 hours
dark) and temperature (25C) controlled cages at
the Marmara University Animal studies labora-
tory and fed by standard 20% protein containing
rat chow.
Experiments were conducted in accordance
with internationally accepted principles for the
care and use of laboratory animals and were ap-
proved by the institutional committee for animal
research.
At the beginning and at the end of the 8 week,
rats were placed in metabolic cages for collection
of 24-hour urine samples. They were sacrificed
with ether anaesthesia and blood samples were
collected by cardiac puncture. Kidneys were ex-
cised. The right kidney was fixed in phosphate
buffered formaldehyde solution for light mi-
croscopy and processed in paraffin.
Electron Microscopic Evaluation
Pieces from the upper pole cortex of the left
kidney were fixed in 0,3mM MgC1 and 0,05%
Alcian blue containing, phosphate buffered
2.5% glutaraldehyde solution and processed in
epon. I191 After being cut and placed on a slide,
tissues were stained with methylene blue in or-
der to localize glomeruli by light microscopy.
Then, the blocks were trimmed down and 60nm
sections were cut and viewed under the electron
microscope.
Basement membrane thickness evaluation
was done under 50,000 magnification on 3
glomeruli for each specimen and at least on
5 plan for each glomerulus by the orthogo-
nal intercept method. Three specimens from
each study group were evaluated for electron
microscopy.
Alcian blue stained particles were assessed
quantitatively in an 1 im
2 area at five different
plans on three glomeruli for three rats in each
group. Also distribution pattern of alcian blue
stained particles were evaluated.
Light Microscopic Evaluation
Kidney cortex samples were fixed in formalde-
hyde solution and processed in paraffin, 5p
section were cut and stained according to the
critical electrolyte concentration technique with
0,3M MgCI2 and 0,5% Alcian blue 8GX (Sigma
cat no: A-5268).[2] Alcian blue staining of GBM
was evaluated at 5 different sites of at least
20 glomeruli for each specimen. Staining was
graded between 0-3+ semi quantitatively
(0 =no staining, 1 + =focal, 2 + =diffuse mild,
3 + prominent).
Also a semi-quantitative assessment of renal
damage was performed on periodic acid shift
and methenamine silver sections. The following
histological findings were considered: mesangial
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expansion, interstitial fibrosis, tubular atrophy,
arteriolar hyalinosis and interstitial inflamma-
tion. Mesangial change was graded from 0-3 +
(0 no change, 1 + mild changes consisting of
an expansion of mesangial matrix or cells, with-
out reduction of capillary lamina; 2 + moderate
changes consisting of an expansion of mesangial
matrix with a reduction of capillary lamina; 3 +
severe changes consisting of an expansion of
mesangial matrix or cells with marked occlusions
of capillary lamina). Interstitial fibrosis and tu-
bular atrophy were graded from 0-3 + (0 =no
change, 1 + changes affected less than 10% of the
biopsy specimen, 2 + changes affecting 10-25%
of the biopsy specimen, 3 + changes affecting
more than 25% of the biopsy specimen). Arterial
hylinosis was graded from 0-3 + (0 no hyalin
deposit; 1 + hyalin deposit <50% of circumfer-
ence; 2 + hyalin deposit > 50 of circumference;
3 + diffuse). Arteriosclerotic changes leading to
reduction of the vascular lumen were graded
from 0-4 + (0 no change; 1 + mild thickening,
less than the luminal diameter; 2 + wall thick-
ness equal to the diameter of the lumen; 3 + wall
thickness greater than diameter of the luminal
diameter; 4 + luminal occlusion). [21]
In each specimen, perpendicular axis of at least
8 glomeruli, sectioned at a vertical line transpass-
ing the glomerular tuft, were measured by ocular
micrometer and the means of two measurements
were averaged. I221 Glomerular capillary areas
were calculated with the "/rr2 formula.
Total number of cell nuclei per glomerular
cross-section of 8 glomeruli were counted for
each specimen. [231
Determination of RBCCh
RBCCh was evaluated with a cationic dye Alcian
blue 8GX (Sigma cat no: A 5268), according to
the method of Levin,I241 with minor modifica-
tions as follows: from whole blood samples,
coagulated with citrate, platelets and leuco-
cytes were removed by the method of Beutler
et al. [25] Red blood cells (RBC) were washed
three times in saline and resuspended in the
buffered solution containing alcian blue at a
final concentration of 250mg/L. After a 30-
minute incubation period at 37C, the RBC sus-
pension was centrifuged and the remaining
alcian blue concentration was measured in the
supernatant by a Shimatsu 2000UV spectropho-
tometer at a wavelength of 650nm. Intra- and
inter-assay coefficients of variation of alcian blue
binding were 5.8% and 7.6%, respectively.
Determination of Urinary GAG
Urinary GAG was measured by a Shimatsu
2000UV spectrophotometer at a wavelength of
520nm in 24-hour urine samples, with a colori-
metric method described by Jong,I261 using 1.9
dimethyleneblue (Aldrich Chem Co, USA) and
bovine kidney heparan sulfate as a standard
(Sigma Cat No H7640). Intra- and inter-assay co-
efficients of variation of urine heparan sulfate
were 2.4% and 15%, respectively.
Urine albumin excretion was determined
by nephalometric kit by Biobak. Plasma glu-
cose was measured by the glucose oxidase
method with a colorimetric kit by Boehringer
(Mannheim, Germany) for the Hitachi 705 auto-
analyzer. Urine and plasma creatinine was
measured by a modified Jaffe method with a
colorimetric kit by Biobak (USA, CA).
Creatinine clearance was calculated using the
formula U.V/P, where U is the urine creatinine,
is the volume and P is the plasma creatinine.
Statistical analyses were performed with an
IBM compatible PC by an Instat II program. All
of the analyses were made by nonparametric
tests. Kruskal-Wallis ANOVA, Mann-Whitney U
tests were used for comparisons and Spearman
rank test was used for correlation analysis. The
results were expressed as mean _
SEM.
RESULTS
At the end of the 8 week study period, fasting
plasma glucose levels were 79,5 + 11,1 mg/dl for
healthy controls and 116,3+19mg/dl for AG
treated healthy rats while diabetic animals had
significantly elevated levels (328,8 61 mg/dl for
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AGDM and 436,2+66,9mg/dl for DC rats
(p<0,05). RBCCh was found to be lower in
diabetic control rats than in the other 3 groups
(p<0,05) (Tab. I). Urinary 24-hour albumin
excretion (UAE) was elevated in the DC group
(277.4 +37.51xg/day, p<0,001) compared with
HC group (106+271xg/day) and AGH (82.4 +
10.7txg/day). AG treated diabetic rats (162.5 +__
21.81xg/day) had lower UAE than diabetic
controls (p<0,05), but it was still high com-
pared with healthy controls (p<0.05). Uri-
nary albumin/creatinine ratio showed similar
results.
Urinary 24-hour heparan sulfate excretion
was 899,4 +158,6 xg/day for healthy controls
while DC rats had significantly higher levels
(2075,6 + 500 p,g/day, p < 0,05). AGDM group
had lower GAG excretion (1050.6 +_ 195 p.g/day)
than DC rats (p < 0,05), and comparable with the
both healthy groups. Urinary GAG/creatinine
ratio displayed similar results.
Urinary albumin excretion was significantly cor-
related with plasma glucose (r =0.87, p <0.0001)
and urinary heparan sulfate excretion (r =0.73,
p < 0.0001) in all study group. A negative correla-
tion was observed between RBCCh and plasma
glucose (r 0.51, p < 0.05), urinary albumin ex-
cretion (r =-0.35, p < 0.05) and urinary heparan
sulfate levels (r 0.61, p < 0.0005).
In electron microscopic evaluation, GBM thick-
ness was 114,6 +4,1nm for AG treated diabetic
rats, 224 _+20,1nm for non-treated diabetic rats,
95,7 7,6nm for healthy controls, and 97,3 + 4,3nm
for AG treated healthy controls. Diabetic groups
had higher GBM thickness than healthy groups
(p<0,001) while AG treated diabetic rats had
lower values compared with diabetic controls
(p < 0,05), and non-diabetic animals.
Healthy control rats had a diffuse distribution
pattern of alcian blue stained particles in the
GBM (Fig. la). In untreated diabetic rats, alcian
blue stained particles were reduced along the
basement membrane and subendothelial deposi-
tions of anionic particles were observed com-
pared to the healthy control group (Fig. lb).
AGDM group glomeruli showed a similar dis-
tribution pattern of alcian blue stained par-
ticles throughout the GBM as healthy controls
(Fig. lc). Also AG treated healthy rats showed
a pattern of distribution similar to healthy
controls.
Alcian blue stained particle count per 1 ixm
2
was 90.6 + 0.6, 36.0 __+ 2.4, 93.8 + 1.1, 98.6 + 1.7 for
AGDM, DC, HC, AGH groups respectively. DC
group have significantly lower level than the
other groups (p < 0.005).
During light microscopic semi-quantitative
evaluation of alcian blue staining, diabetic con-
trols (Fig. 2a) displayed less staining than
healthy rats (Fig. 2b) (p<0.01). Alcian blue
staining of glomeruli in AGDM group (Fig. 2c)
was strong than DC group (p <0.05) while it
wasn’t different than HC group.
Mesangial matrix that was evaluated semi-
quantitatively appeared to be expanded in
untreated diabetic rats compared with healthy
TABLE Biochemical parameters of rats at the end of the study period
AGDM DC HC AGH
Glucose (mg/dl)
RBCCh (ng alcian blue/106 RBC)
Albuminuria (lag/day)
Albumin/creatine (lag/mg)
Urinary Heparan sulfate (tag/day)
Urinary Heparan sulfate/creatine
(lag/rag creatine)
*p < 0.05 vs. healthy rats.
*p < 0.05 vs. other groups.
*p < 0.05 vs. healthy controls.
p < 0.001 vs. healthy groups, p < 0.05 vs. AGDM.
3p < 0.05 vs. other groups. p < 0.01 vs. healthy rats, p < 0.05 vs. AGDM.
328.8 61" 436.2 66.9* 79.5 11.1 126.3 +__ 19
465.5 3.9 367.5 _+ 32.9 423.4 __+ 14.8 468.6 _
5.5
162.5 21.8’ 277.4 37.53 106 27 82.4 + 10.7
7.36 _+ 1.4’ 22.8 7.8 0.42 0.12 0.39 0.16
1050.6 195 2075.6 +__ 50533 899.4 158.6 956 68.7
4.31 28.8 _+ 11.4 2.38 0.9 1.16 0.16






FIGURE 1 Electron micrographs of glomerular basement
membranes from rats: (a) Diffuse distribution pattern of
alcian blue stained particles (arrows) in healthy control rat
having higher particle number-density (original magnifica-
tion: 50000, bar: 100nm); (b) Subendothelial depositions
(short arrows) of alcian blue stained particles (arrows) in
untreated-diabetic rat having lower particle number-density
(original magnification: 50000, bar: 100nm); (c) Diffuse
distribution pattern of alcian blue stained particles (arrows)
of AG treated-diabetic rat having higher particle number-
density (original magnification: 50 000, bar: 100 nm).
(c)
FIGURE 2 Light microscopic photographs of rat glomeruli
stained with alcian blue: Glomerular basement membrane of
non-treated diabetic rats displayed less staining of alcian
blue (a) than the healthy controls (b). GBM of the AG treated
diabetic rats (c) showed a very similar staining pattern with
healthy rats. Magnification: x400.
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TABLE II Semiquantitative evaluation (number of biopsies in relation to score) for different
parameters in renal specimens from diabetic and healthy rats
AGDM DC HC AGH
(n 11) (n 12) (n 8) (n 8)
0 2 3 0 2 3 0 2 3 0 2 3
alcian blue staining ofGBM 0 2 6 3 2 8 2 0* 0 1 2 5 0 0 4 4
Mesengial matrix expansion 0 2 4 5 0 1 4 6 5 3 0 0 6 2 0 0
interstitial inflammation 5 6 0 0 2 9 0 7 1 0 0 8 0 0 0
interstitial fibrosis 8 3 0 0 8 3 0 7 1 0 0 8 0 0 0
tubuleratrophy 10 1 0 0 9 2 0 8 0 0 0 8 0 0 0
arteriolarhyalinosis 4 4 3 0 3 7 2 0 7 1 0 0 8 0 0 0
arteriolosclerosis 3 7 1 0 4 6 2 0 8 0 0 0 7 1 0 0
*p < 0,0001 vs. other groups.
*p < 0,0001 diabetic rats vs. healthy rats.
p < 0,05 vs. healthy groups. p < 0,001 diabetic rats vs. healthy rats.
p < 0,05 diabetic rats vs. healthy rats.
controls (p < 0,001). AG treated diabetic rats had
expanded matrix similar with diabetic controls.
Basement membrane thickness, evaluated semi-
quantitatively by light microscopy, was also
found to be greater in the diabetic controls com-
pared with healthy control and AG treated dia-
betics (p < 0.01) (see Tab. II).
Total glomerular cell counts were 26,9 + 1.6
for AGDM; 31,0 + 1,1 for DC; 26,6 + 1,0 for HC
and 22,6 + 1,0 forAGH groups. The cell count of
diabetic controls was significantly higher than
that of healthy rats (p < 0,001). AG treated dia-
betic rats had a lower cell count than diabetic
controls (p <0,01). Glomerular diameters were
42.2 0.3 txm, 46.3 + 0.8 txm, 40.4 + 0.6 xm, and
40.3 +l.0xm for AGDM, DC, HC and AGH
groups respectively. Diabetic rats had a higher
diameter and surface area compared with
healthy animals (p <0.05). AG treated diabetic
rats and untreated diabetic rats had a similar
glomerular diameter.
DISCUSSION
The results of this study demonstrate that AG
reduces albuminuria and prevents glomerular
basement membrane thickening in STZ induced
diabetic rats. Over the 8-week study, there was a
significant increase in urinary albumin excretion
in diabetic rats. In contrast AG therapy retarded
the Increase in albuminuria in diabetic rats,
resulting in levels similar to those observed in
control rats at 8-wk. These results are in concord-
ance with the findings of Ellis et al., who have
shown a decrease in urinary albumin excretion
and widening of the GBM in STZ induced Lewis
rats by AG treatment,7J and Edelstein et al., who
have reported that AG ameliorates albuminuria
in diabetic hypertensive rats. Illl On the other
hand, there are also conflicting results in the liter-
ature. In a type 2 model of diabetes, Yamauchi
et al., have shown thatAG treatment has no effect
on UAE although it reduces GBM thickness. [27]
Soulis et al., have reported that the increased
glomerular basement membrane thickness in di-
abetic rats is not affected by aminoguanidine,
irrespective of duration or timing of therapy. I81
Our study confirms that urinary GAG excre-
tion is elevated in non-treated diabetic rats as
shown before in diabetic rats by Reddi,I15,61 and
in diabetic humans by McAuliffe.7J We observed
a significant decrease in urinary GAG excretion
in AG treated diabetic rats compared with non-
treated diabetic rats. Urinary GAG excretion was
significantly correlated with albumin excretion in
all study groups. This might be indicate that in-
creased loss of proteoglycans from diabetic kid-
neys is prevented by aminoguanidine treatment.
This is the first report of such an effect.
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This study also shows a significant quantitative
reduction of alcian blue binding to RBC in un-
treated diabetic rats. Aminoguanidine treated di-
abetic rats have similar levels of alcian blue
binding to RBC as healthy rats. As alcian blue
binding of RBCs is an expression of the anionic
charge of the RBC surface,[14,241 this result indi-
cates that RBC charge is reduced in non-treated
diabetic rats while it is protected inAG treated di-
abetics. RBCCh measurements were negatively
correlated with urinary albumin and GAG excre-
tion in all study groups. Those results are in
agreement with Gambaro’s findings who has
suggested that RBCCh could mirror the nega-
tive charge of the glomerular basement mem-
brane. [14,24] AG treatment seems to protect the
anionic content of both erythrocyte and glomeru-
lar basement membrane.
Our results suggest that treatment of diabetic
rats withAG prevents this loss of glycosaminogly-
cans from the GBM. As it has been proposed be-
fore that an increased loss of glycosaminoglycans
from the GBM alters glomerular charge selectivity,
leading to loss of albumin in the urine.[15-17,281
Results of biochemical parameters are in
agreement with electron microscopic and light
microscopic findings. In electron microscopic ex-
amination total number of alcian blue stained
particles in I pm2 area on the GBM was de-
creased in untreated diabetic rats compared with
healthy animals. On the other hand, AG treated
diabetic rats had a similar counts of anionic par-
ticles with healthy rats.
Since Mg++ ions, in concentrations used in
this study, displace carboxylic groups but not
sulphate groups, the alcian blue stained struc-
tures represent anionic sites of sulphated gly-
cosaminoglycans, primarily heparan sulfate in
the glomeruli. I291 As alcian blue only stains the
sulphated GAGs, loss of GAGs from the GBM
could conceivably be due to either decreased
production of sulphation, or adherence to the
structural proteins. Another explanation for re-
duction of alcian blue stained particles could be
thickening of the GBM itself. As GBM widens,
the density of the particles in imm2 area seems
to be decreased.
Besides the preservation of anionic charge,
there are many suggested mechanisms explain-
ing favorable effects of AG. Sugimoto et al., have
shown that carboxymethyllysine possibly en-
hances the expression of inducible nitric oxide
synthase by stimulating the expression of TNF-
c in diabetic rat glomeruli. Treatment with
AG reduces the expression of TNF-c and in-
traglomerular NOa/NO3 production (30). The
study of Osicka et al., indicates that AG prevents
diabetes induced changes in lysosomal process-
ing (31). Most remarkable finding is that AG
treatment prevented the rise in glomerular pro-
tein kinase C activity. Prevention of albuminuria
by aminoguanidine has also been associated
with the normalization of glomerular protein
kinase C (32). In the view of these findings the
exact mechanism still remains to be elucidated.
In conclusion, AG treatment reduces urinary
albumin excretion, prevents GBM thickness and
protects from the loss of GBM anionic content in
diabetic rats. Preservation of anionic charges of
the GBM seems to be one of the mechanisms by
which aminoguanidine ameliorates the albumin-
uria in diabetic rats.
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